Incyte upgraded to Market Perform at SVB after ruxolitinib XR CRL, Zynz approval
The Fly

Incyte upgraded to Market Perform at SVB after ruxolitinib XR CRL, Zynz approval

SVB Securities upgraded Incyte to Market Perform from Underperform with a price target of $61, up from $60, following several regulatory updates. The XR version of ruxolitinib was "not fundamentally part of our valuation," but it "is a key factor" in Incyte’s lifecycle management program for Jakafi, which loses IP protection in December 2028, the analyst tells investors. With the ruxolitinib XR CRL pressuring shares and the accelerated approval for Zynz in Merkel cell carcinoma "adding fundamental value to our valuation," the firm prefers to step to the sidelines until the next steps for the LIMBER program are spelled out and "the true commercial trajectory" for Opzelura in atopic derm and vitiligo become apparent, SVB tells investors.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on INCY:

Related Articles
TheFlySyndax and Incyte announce publication of positive Niktimvo results in GVHD
TheFlyNvidia, ARM initiated: Wall Street’s top analyst calls
TheFlyIncyte downgraded to Hold from Buy at Truist
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App